Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 03:59:57 2024-03-28 pm EDT 5-day change 1st Jan Change
6.69 USD +0.90% Intraday chart for Cytek Biosciences, Inc. +1.21% -26.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing MT
Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance MT
Cytek Biosciences, Inc. Announces Appointment of Patrik Jeanmonod as Head of Corporate Development Analytics CI
Cytek Biosciences, Inc. Announces CFO Changes CI
Cytek Biosciences Unveils New Manufacturing Facility in Wuxi, China MT
Cytek Biosciences, Inc. Opens A New 50,000-Square-Foot Facility in Wuxi, China CI
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating MT
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023. CI
Cytek Biosciences, Inc. Provides Earnings Guidance for the Year Ended December 31, 2024 CI
Cytek Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Cytek Biosciences, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Cytek Biosciences Agrees to Flow Cytometry Collaboration With Centre for Genomic Regulation, Pompeu Fabra University MT
Cytek Biosciences, Inc. Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries CI
Cytek Seeks Merger and Acquisitions CI
Transcript : Cytek Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 CI
Cytek Biosciences Introduces the Cytek Orion? Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow Cytometry CI
Stephens Initiates Cytek Biosciences With Overweight Rating, Price Target is $9 MT
Cytek Biosciences Insider Sold Shares Worth $120,600, According to a Recent SEC Filing MT
Morgan Stanley Trims Price Target on Cytek Biosciences to $7 From $8, Maintains Equalweight Rating MT
Tranche Update on Cytek Biosciences, Inc.'s Equity Buyback Plan announced on May 19, 2023. CI
Cytek Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (CTKB) CYTEK BIOSCIENCES Posts Q3 Revenue $48M, vs. Street Est of $55.5M MT
Transcript : Cytek Biosciences, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Cytek Biosciences, Inc. Provides Revenue Guidance for the Year 2023 CI
Chart Cytek Biosciences, Inc.
More charts
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
6.63 USD
Average target price
10.2 USD
Spread / Average Target
+53.85%
Consensus
  1. Stock
  2. Equities
  3. Stock Cytek Biosciences, Inc. - Nasdaq
  4. News Cytek Biosciences, Inc.
  5. Earnings Flash (CTKB) CYTEK BIOSCIENCES Posts Q2 Revenue $40.2M, vs. Street Est of $39.6M